Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naive patients: a Phase 2 "proxy" study

被引：0
|
作者：
Gane, Edward J. [1 ]
Kocinsky, Hetal [2 ]
Schwabe, Christian [3 ]
Mader, Michael [2 ]
Suri, Vithika [3 ]
Donohue, Mary K. [2 ]
Huang, Mingjun [2 ]
Hui, James [2 ]
Yang, Joanna [2 ]
Apelian, David [2 ]
机构：
[1] Auckland Hosp, New Zealand Liver Transplant Unit, Auckland, New Zealand
[2] Achill Pharmaceut, New Haven, CT USA
[3] Auckland Clin Studies Ltd, Grafton, New Zealand
来源：
HEPATOLOGY | 2014年 / 60卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LB-23
引用
收藏
页码：1281A / 1282A
页数：2
相关论文
共 50 条
  • [41] Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study
    Kowdley, Kris V.
    Gordon, Stuart C.
    Reddy, K. Rajender
    Rossaro, Lorenzo
    Bernstein, David
    An, Di
    Svarovskaia, Evguenia
    Hyland, Rob H.
    Pang, Phil
    Symonds, William T.
    McHutchison, John G.
    Muir, Andrew J.
    Pockros, Paul J.
    Pound, David
    Fried, Michael W.
    GASTROENTEROLOGY, 2014, 146 (05) : S926 - S926
  • [42] SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAIVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY
    Kowdley, K. V.
    Stuart, G. C.
    Reddy, R. K.
    Rossaro, L.
    Bernstein, D. E.
    An, D.
    Svarovskaia, E. S.
    Hyland, R. H.
    Pang, P. S.
    Symonds, W. T.
    Mchutchison, J. G.
    Muir, A. J.
    Pockros, P. J.
    Pound, D.
    Fried, M. W.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S23 - S24
  • [43] Concordance Between Sustained Virologic Response Week 12 (SVR12) and SVR24 in Genotype 1 Hepatitis C Virus Patients Receiving Interferon-Free Treatment in the SOUND-C2 Study
    Zeuzem, Stefan
    Mensa, Federico J.
    HEPATOLOGY, 2013, 58 (04) : 1516 - 1516
  • [44] Real-life Hepatitis C treatment: effectiveness of 8 or 12 week Sofosbuvir/Ledipasvir in Genotype 1 non-cirrhotic treatment-naive mono or HIV-coinfected patients
    Sanchez-Conde, Matilde
    Filigheddu, Maria Teresa
    Losa, Juan E.
    Quereda, Carmen
    Vivancos-Gallego, Maria J.
    Ayerbe, Cristina Gomez
    Perez-Elias, Maria J.
    Moreno, Santiago
    Moreno, Ana
    HEPATOLOGY, 2016, 64 : 999A - 999A
  • [45] An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naive Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
    Asselah, Tarik
    Moreno, Christophe
    Sarrazin, Christoph
    Gschwantler, Michael
    Foster, Graham R.
    Craxi, Antonio
    Buggisch, Peter
    Ryan, Robert
    Lenz, Oliver
    Scott, Jane
    Van Dooren, Gino
    Lonjon-Domanec, Isabelle
    Schlag, Michael
    Buti, Maria
    PLOS ONE, 2016, 11 (07):
  • [46] SIMEPREVIR (SMV) PLUS DACLATASVIR (DCV) AND SOFOSBUVIR (SOF) IN TREATMENT-NAIVE AND -EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 OR 4 INFECTION AND DECOMPENSATED LIVER DISEASE: INTERIM RESULTS FROM THE PHASE II IMPACT STUDY
    Lawitz, E.
    Poordad, F.
    Gutierrez, J.
    Kakuda, T.
    Picchio, G.
    De La Rosa, G.
    Beets, G.
    Vandevoorde, A.
    Van Remoortere, P.
    Jacquemyn, B.
    Quinn, G.
    Luo, D.
    Ouwerkerk-Mahadevan, S.
    Vijgen, L.
    Van Eygen, V.
    Beumont, M.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S266 - S267
  • [47] SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R
    Sulkowski, M. S.
    Bourliere, M.
    Bronowicki, J. -P.
    Streinu-Cercel, A.
    Preotescu, L.
    Asselah, T.
    Pawlotsky, J. -M.
    Shafran, S.
    Pol, S.
    Caruntu, F. A.
    Mauss, S.
    Larrey, D.
    Haefner, C.
    Datsenko, Y.
    Stern, J. O.
    Kubiak, R.
    Boecher, W.
    Steinmann, G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S30 - S30
  • [48] High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study
    Abergel, A.
    Hezode, C.
    Asselah, T.
    Larrey, D.
    Gournay, J.
    Loustaud-Ratti, V.
    Martino, V. D.
    Hubert, I. F.
    Samuel, D.
    Chanteranne, B.
    Dodel, M.
    Faure, F.
    Pereira, B.
    Lamblin, G.
    Campos, C.
    Muti, L.
    Reymond, M.
    Teilhet, C.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S110 - S110
  • [49] The role of cholesterol on sustained virological response (SVR) in the treatment of genotype-1 infected hepatitis C (cHC) patients with peginterferon Alfa-2a (PEG) and ribavirin (RBV)
    Mauss, Stefan
    Zehnter, Elmar
    Hueppe, Dietrich
    Kaiser, Stephan
    Becker, Klaus
    Lutz, Thomas
    Heyne, Renate
    John, Christine
    Moog, Gero
    Schober, Andreas
    Pfaff, Rainer
    Zipf, Andreas
    Racky, Stefan A.
    Lohmeyer, Jueregn
    Bokemeyer, Bernd
    Kallinowski, Birgit
    Witthoeft, Thomas
    Alshuth, Ulrich
    GASTROENTEROLOGY, 2008, 134 (04) : A829 - A829
  • [50] ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS
    Lawitz, E.
    Poordad, F.
    DeJesus, E.
    Kowdley, K.
    Gaultier, I.
    Cohen, D.
    Xie, W.
    Larsen, L.
    Pilot-Matias, T.
    Menon, R. M.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S470 - S470
12345